By proceeding, you agree to our Terms of Use and Privacy Policy.
Giovanni is the right leader for Xcovery,” said Lieming Ding, M.D., Chairman of the Board. “For the past two years, Giovanni has been successfully driving forward the ensartinib and vorolanib clinical programs as the company CMO.
Talks About #Oncology #Clinicaltrials #Clinicaldevelopment
Preferred Locations #NorthAmerica
The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine.